Country for PR: China
Contributor: PR Newswire Asia (China)
Monday, December 26 2022 - 23:04
MindRank Announces U.S. FDA Clearance of IND Application for MDR-001, a Novel GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity
SHANGHAI and HANGZHOU, China, Dec. 26, 2022 /PRNewswire-AsiaNet/ --

MindRank, an artificial intelligence (AI)-empowered drug discovery company, 
announces today that the U.S. Food and Drug Administration (FDA) has cleared 
the company's Investigational New Drug (IND) application for MDR-001, an oral 
small-molecule glucagon-like peptide 1 receptor agonist (GLP-1 RA), for the 
treatment of obesity and type 2 diabetes mellitus (T2DM), respectively. 
MindRank expects to initiate a Phase I safety study in the first quarter of 

Empowered by Mindrank's proprietary AI drug discovery platform, Molecule Pro™, 
it just took the company 19 months to obtain the IND approval since the MDR-001 
program was initiated. With fewer than 100 chemical compounds synthesized and 
tested, the preclinical candidate was discovered.

"By facilitating novel small molecule drug design with desired drug-like 
properties, we believe our AI platform can significantly improve the 
pre-clinical R&D efficiency. The FDA IND approval of MDR-001 is a solid 
validation for the potential of our AI platform." commented Zhangming Niu, CEO 
of MindRank. This heralds the transition of MindRank from a discovery-stage to 
a clinical-stage AI-empowered biotechnology company.

About MDR-001

MDR-001 is a novel, orally bioavailable small-molecule GLP-1 RA discovered 
using MindRank's proprietary AI platform, Molecule Pro™. In the comprehensive 
preclinical studies, MDR-001 has demonstrated excellent functional potency and 
selectivity, with favorable ADME properties and oral bioavailability, as well 
as desirable pharmacokinetics and tolerability. MDR-001's superior preclinical 
efficacy and safety profiles indicate its best-in-class potential for Obesity 
and T2DM indications with large unmet medical needs.

About MindRank

MindRank is an artificial intelligence (AI)-empowered drug discovery company. 
By leveraging its proprietary AI platform, Molecule Pro, the company aims to 
significantly accelerate the drug discovery process and deliver small molecule 
drugs with desirable efficacy and safety profiles.

To learn more, visit .

SOURCE: MindRank